Neurocrine Biosciences (NBIX) Stock Analysis

What Neurocrine Biosciences does

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

Key metrics

ETFs linked to NBIX

Broad-market and Healthcare sector ETFs an investor holding Neurocrine Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NBIX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Neurocrine Biosciences?

Neurocrine Biosciences trades under the ticker NBIX on NASDAQ.

Which exchange is NBIX listed on?

NBIX is listed on NASDAQ.

What sector does Neurocrine Biosciences operate in?

Neurocrine Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NBIX in a portfolio?

PortView shows NBIX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.